GB201513176D0 - Novel methods for inducing an immune response - Google Patents

Novel methods for inducing an immune response

Info

Publication number
GB201513176D0
GB201513176D0 GBGB1513176.6A GB201513176A GB201513176D0 GB 201513176 D0 GB201513176 D0 GB 201513176D0 GB 201513176 A GB201513176 A GB 201513176A GB 201513176 D0 GB201513176 D0 GB 201513176D0
Authority
GB
United Kingdom
Prior art keywords
inducing
immune response
novel methods
novel
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1513176.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1513176.6A priority Critical patent/GB201513176D0/en
Publication of GB201513176D0 publication Critical patent/GB201513176D0/en
Priority to PCT/EP2016/067622 priority patent/WO2017017050A1/en
Priority to PCT/EP2016/067621 priority patent/WO2017017049A1/en
Priority to EP16745090.7A priority patent/EP3328421A1/en
Priority to JP2018503747A priority patent/JP2018524393A/ja
Priority to US15/747,545 priority patent/US20180216081A1/en
Priority to BE20165610A priority patent/BE1023916A9/fr
Priority to EP16741946.4A priority patent/EP3328420A1/en
Priority to CA2993371A priority patent/CA2993371A1/en
Priority to EA201890355A priority patent/EA201890355A1/ru
Priority to ARP160102263A priority patent/AR105470A1/es
Priority to BR112018001572A priority patent/BR112018001572A2/pt
Priority to AU2016301029A priority patent/AU2016301029B2/en
Priority to CN201680056024.6A priority patent/CN108135991A/zh
Priority to MX2018001213A priority patent/MX2018001213A/es
Priority to MX2018001215A priority patent/MX2018001215A/es
Priority to KR1020187005661A priority patent/KR20180034589A/ko
Priority to US15/747,671 priority patent/US11110159B2/en
Priority to CA2993277A priority patent/CA2993277A1/en
Priority to CN201680043249.8A priority patent/CN108367061A/zh
Priority to BE20165611A priority patent/BE1023915B1/fr
Priority to BR112018001683A priority patent/BR112018001683A2/pt
Priority to JP2018504131A priority patent/JP2018521666A/ja
Priority to IL257071A priority patent/IL257071A/en
Priority to US16/986,413 priority patent/US20210060150A1/en
Priority to US17/397,379 priority patent/US20210386846A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1513176.6A 2015-07-27 2015-07-27 Novel methods for inducing an immune response Ceased GB201513176D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
JP2018504131A JP2018521666A (ja) 2015-07-27 2016-07-25 新規アデノウイルス
AU2016301029A AU2016301029B2 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response
MX2018001213A MX2018001213A (es) 2015-07-27 2016-07-25 Nuevos metodos para inducir una respuesta inmunitaria.
EP16745090.7A EP3328421A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response
JP2018503747A JP2018524393A (ja) 2015-07-27 2016-07-25 免疫応答を誘導するための新規方法
US15/747,545 US20180216081A1 (en) 2015-07-27 2016-07-25 Novel adenovirus
BE20165610A BE1023916A9 (fr) 2015-07-27 2016-07-25 Nouvel adenovirus
EP16741946.4A EP3328420A1 (en) 2015-07-27 2016-07-25 Novel adenovirus
CA2993371A CA2993371A1 (en) 2015-07-27 2016-07-25 Novel adenovirus
EA201890355A EA201890355A1 (ru) 2015-07-27 2016-07-25 Новые способы индукции иммунного ответа
ARP160102263A AR105470A1 (es) 2015-07-27 2016-07-25 Métodos para inducir una respuesta inmune
BR112018001572A BR112018001572A2 (pt) 2015-07-27 2016-07-25 método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
PCT/EP2016/067622 WO2017017050A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response
CN201680056024.6A CN108135991A (zh) 2015-07-27 2016-07-25 新型腺病毒
PCT/EP2016/067621 WO2017017049A1 (en) 2015-07-27 2016-07-25 Novel adenovirus
MX2018001215A MX2018001215A (es) 2015-07-27 2016-07-25 Adenovirus novedoso.
KR1020187005661A KR20180034589A (ko) 2015-07-27 2016-07-25 면역 반응을 유도하기 위한 신규한 방법
US15/747,671 US11110159B2 (en) 2015-07-27 2016-07-25 Methods for inducing an immune response
CA2993277A CA2993277A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response
CN201680043249.8A CN108367061A (zh) 2015-07-27 2016-07-25 用于诱导免疫应答的新方法
BE20165611A BE1023915B1 (fr) 2015-07-27 2016-07-25 Nouveaux procedes pour induire une reponse immunitaire
BR112018001683A BR112018001683A2 (pt) 2015-07-27 2016-07-25 adenovírus recombinante, composição, uso de um adenovírus ou uma composição, e, adenovírus de símio não humano.
IL257071A IL257071A (en) 2015-07-27 2018-01-22 New methods for inducing an immune response
US16/986,413 US20210060150A1 (en) 2015-07-27 2020-08-06 Novel adenovirus
US17/397,379 US20210386846A1 (en) 2015-07-27 2021-08-09 Novel methods for inducing an immune response

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
GB201513176D0 true GB201513176D0 (en) 2015-09-09

Family

ID=54106649

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1513176.6A Ceased GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response

Country Status (15)

Country Link
US (4) US20180216081A1 (https=)
EP (2) EP3328420A1 (https=)
JP (2) JP2018524393A (https=)
KR (1) KR20180034589A (https=)
CN (2) CN108135991A (https=)
AR (1) AR105470A1 (https=)
AU (1) AU2016301029B2 (https=)
BE (2) BE1023916A9 (https=)
BR (2) BR112018001572A2 (https=)
CA (2) CA2993277A1 (https=)
EA (1) EA201890355A1 (https=)
GB (1) GB201513176D0 (https=)
IL (1) IL257071A (https=)
MX (2) MX2018001213A (https=)
WO (2) WO2017017049A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP7466271B2 (ja) * 2016-03-31 2024-04-12 ザ ヨーロピアン モレキュラー バイオロジー ラボラトリー アデノウイルスコートタンパク質由来送達賦形剤
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3697919A1 (en) * 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
EP3697902A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals S.A. Enhanced promoter
JP2021500880A (ja) 2017-10-16 2021-01-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ２つの発現カセットを有するサルアデノウイルスベクター
WO2019076877A1 (en) * 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ADENOVIRAL VECTORS FOR REPLICATION
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
EP3807298A1 (en) * 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
CN112423786B (zh) * 2018-08-10 2024-03-22 南特生物公司 用于病毒感染的细胞佐剂
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
WO2021067448A1 (en) 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
WO2022120176A2 (en) * 2020-12-04 2022-06-09 Gritstone Bio, Inc. Compositions and methods of use thereof
CA3226978A1 (en) * 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Tuberculosis vaccines
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727602B2 (en) 1995-09-01 2000-12-14 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
CA2563500C (en) * 2004-04-28 2016-06-28 The Trustees Of The University Of Pennsylvania Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
DK2457926T3 (da) * 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
WO2006133911A2 (en) * 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
CN102131920B (zh) 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
BR112012018669A2 (pt) * 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
US9526777B2 (en) * 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
CN106822883A (zh) * 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2013123579A1 (en) 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.

Also Published As

Publication number Publication date
JP2018521666A (ja) 2018-08-09
BE1023915A9 (fr) 2018-01-24
US20180216081A1 (en) 2018-08-02
BE1023916A9 (fr) 2018-02-12
MX2018001215A (es) 2018-04-13
AR105470A1 (es) 2017-10-04
WO2017017049A1 (en) 2017-02-02
BE1023916A1 (fr) 2017-09-12
EP3328420A1 (en) 2018-06-06
JP2018524393A (ja) 2018-08-30
BE1023915A1 (fr) 2017-09-12
BE1023915B1 (fr) 2018-01-31
AU2016301029A1 (en) 2018-02-01
US20210386846A1 (en) 2021-12-16
CN108367061A (zh) 2018-08-03
MX2018001213A (es) 2018-04-13
EA201890355A1 (ru) 2018-08-31
US20210060150A1 (en) 2021-03-04
BR112018001572A2 (pt) 2018-11-06
US20180250375A1 (en) 2018-09-06
BR112018001683A2 (pt) 2018-09-18
WO2017017050A1 (en) 2017-02-02
CN108135991A (zh) 2018-06-08
CA2993277A1 (en) 2017-02-02
IL257071A (en) 2018-03-29
EP3328421A1 (en) 2018-06-06
BE1023916B1 (fr) 2018-01-22
US11110159B2 (en) 2021-09-07
KR20180034589A (ko) 2018-04-04
AU2016301029B2 (en) 2019-08-22
CA2993371A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL257071A (en) New methods for inducing an immune response
ZA201803644B (en) An adjuvant
IL257053A (en) Predicting immune response
GB201621686D0 (en) Novel methods for inducing an immune response
GB201519481D0 (en) Immunomodulatory antibodies
GB2538731B (en) Methods
GB201503534D0 (en) Novel method
GB2541725B (en) Weights system
GB201410262D0 (en) Novel method
GB201512372D0 (en) Novel method
ZA201605955B (en) Novel methods for inducing an immune response
GB201518762D0 (en) Methods
GB201508927D0 (en) Methods
SG11201703801SA (en) Novel methods
GB201509862D0 (en) Novel device
GB201515655D0 (en) Methods
GB201416773D0 (en) Novel Methods For Including An Imune Response
GB201511951D0 (en) An eyeguard
SG10201500850SA (en) Assembly apparatus
GB2528104B (en) Photographic-flash response system
GB201517176D0 (en) An apparatus
GB201515354D0 (en) Novel Device
GB201512609D0 (en) Methods
HK1260192A1 (en) Methods and means for inducing an immune response
GB201613130D0 (en) Novel methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)